Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
24seven - Thank you. I have never left. Still invested like before.
Liquid Biopsies - New Cancer Detection Technique Has Enormous Potential for Life Science Stocks
(This aspect of AEMD has taken a backstage recently)
Read more: New Cancer Detection Technique Has Enormous Potential for Life Science Stocks - Illumina (NASDAQ:ILMN) - 24/7 Wall St. http://247wallst.com/healthcare-business/2014/11/11/new-cancer-detection-technique-has-enormous-potential-for-life-science-stocks/#ixzz3Inn1RpYM
Follow us: @247wallst on Twitter | 247wallst on Facebook
Aethlon Medical’s Hemopurifier Used to Treat Ebola Patient
(Repost)
http://www.fdanews.com/articles/167816-aethlon-medicals-hemopurifier-used-to-treat-ebola-patient
Thank you for explaining that.
The SEC filing says 376,024 derivative securities acquired (A). I do not see any notification of securities being sold. Maybe I am missing something. Can you/someone explain?
From - Exosome rna
SELECTBIO invites you to its 2nd Annual Circulating Biomarkers Conference. This conference held in the city of Boston close to world-leading research institutions and hospitals seeks to bring together academic researchers, clinician-scientists, as well as researchers from companies all focusing on various classes of biomarkers.
Don’t miss the special session on exosomes – Monday, 24 March 2014
Session Title: Methodologies for Studying Exosomes, Microvesicles [Extracellular Vesicles, EVs]
Session Chair: Sasha Vlassov, PhD
13:45
Xandra Breakefield Keynote PresentationExtracellular Vesicles as Biomarkers and Saboteurs for Glioblastoma
Xandra Breakefield, Professor, Massachusetts General HospitalGlioblastomas are highly malignant brain tumors that have defied therapy. Extracellular vesicles released by these tumors provide a means to analyze the mutant RNA, including mutant IDH1 and EGFR, within the tumors by sampling serum/plasma and cerebral spinal fluid. These biomarkers can provide insights into the mutations driving the tumor and the response of patients to therapy, including concomitant changes in the mutation levels and profiles. These tumor vesicles are also thought to be used by gliomas to modify normal cells in their environment through extracellular delivery of RNA and proteins. Our work supports transfer of miRNA via tumor vesicles to microglia thereby participating in a change in their phenotype.
14:30 A Rapid and Non-destructive Magnetic Beads-based Exosome Isolation and Enrichment Method
Kenneth Henry, Senior Research Scientist, JSR Micro, Inc.In order to isolate exosomes from various body fluids and cell culture supernatants, we have successfully developed ExoCap, which utilizes a magnetic beads based isolation method. ExoCap consists of magnetic particles coupled with antibodies that recognize antigens on the exosome surface, an irrigation solution, and a reagent that releases the captured exosomes for analysis. The antibodies against CD9, CD63, CD81, and EpCAM were specifically selected for this kit. ExoCap can separate easily exosomes within 30 minutes, without ultracentrifuge or any special equipment. A sample amount of 0.1mL is sufficient. In addition, it is an animal free system which is superior to other methods for mass analysis. Moreover, this method enables non-destructive purification of exosomes. To confirm exosomal isolation from diverse body fluids (such as human serum, plasma, urine) and cell culture media, exosomes were examined by western blot, particle size distribution measurement, and scanning transmission electron microscopy (TEM). Exosomes isolated by ExoCap had a lipid bilayer membrane, showed a particle size distribution around 100nm, and expressed tetraspanin molecules.Authors:
Kenneth Henry, Ph.D, Senior Research Scientist, Life Sciences, JSR Micro, Inc.
Tetsuji Yamaguchi, Ph.D. JSR Life Sciences
15:00 Heparin Affinity Purification of Extracellular Vesicles
Leonora Balaj, Research Fellow, Massachusetts General HospitalExtracellular vesicles (EVs) are membrane vesicles released by cells. They carry active biomolecules which can be transferred to recipient cells. Isolation and purification of EVs from in vitro conditioned culture media and in vivo biofluids is still a major challenge and the most widely used isolation method still remains ultracentrifugation (UC) which requires expensive equipment and only partially purifies EVs due to co-pelleting of proteins and lipids. Affinity purification of biomolecules is an efficient way to achieve high purity without requiring expensive equipment. Previously we have shown that heparin blocks EV uptake in mammalian cells in culture, suggesting a possible direct EV/heparin interaction. Here we show that EVs can be purified from conditioned media using heparin-coated agarose beads. We directly compared heparin-purified EVs to UC prepared and kit-isolated EVs and we show that we can efficiently isolate EVs a higher purity than UC, kit-isolated EVs and even sucrose gradient-purified EVs. Importantly these, heparin-purified EVs retained the RNA content, morphology, and uptake dynamics of UC-isolated EVs. In conclusion, we have discovered a simple and effective way to isolate a highly pure population of EVs using their affinity for heparin.
15:30 Coffee Break and Networking with Exhibitors in the Exhibit Hall
16:00 New Biosensor Platform for the Isolation and Analyses of Microvesicles
Hakho Lee, Assistant Professor, Harvard Medical SchoolThis presentation will review new biosensor platforms developed in our laboratory for microvesicle analyses. Specifically, I will describe 1) microfluidic systems that can enrich microvesicles from native clinical specimen, and 2) microNMR sensors that can molecularly profile microvesicles. Clinical applications of these platforms on cancer detection will also be discussed.
16:30 A Hybrid Extracellular vesicle/virus Vector System for Gene Therapy Applications
Casey Maguire, Assistant Professor of Neurology, Harvard Medical School/Mass General HospitalObtaining tissue-restricted transgene expression after intravenous (i.v.) injection of AAV vectors is a challenging task, especially for the brain, as the majority of vector is taken up by the liver. Although some vectors can cross the intact blood-brain barrier, improvements are still needed. Additionally, pre-existing antibodies against AAV can remove vector from the circulation. Other studies have shown that association of virus vectors with nanoparticles, such as microbubbles and cationic liposomes can alter the vector biodistribution to preferred sites. Another nanoparticle which may offer utility to the field of viral vector gene delivery are extracellular vesicles(EVs). EVs are small (50-200 nm in diameter) membrane limited structures naturally secreted by many cell types. We have recently shown that EV-associated AAV vectors (EV-AAV, a.k.a vexosomes) can deliver genes more efficiently on a genome copy per cell basis than AAV vectors alone using cultured cells. In the current study we are using the EV-AAV for targeted gene delivery to the brain after i.v. injection in mice. To investigate if EV-AAV can be targeted to the brain via over-expression of specific ligands on the EV surface we injected nude mice with EV-AAV9-Fluc or EV-AAV9-Fluc with a brain targeting peptide (RVG) fused to a trasmembrane domain.Enhanced transduction of the brain was observed with the RVG peptide compared to untargeted EV-AAV. The brain:peripheral organ transduction ratio was significantly higher for RVG-EV-AAV compared to standard AAV9. This work has provides the first evidence for the in vivo use of EV-AAV for gene therapy.
17:00 Large Oncosomes as a Novel Source of Circulating DNA and miRNA in Cancer
Dolores Di Vizio, Associate Professor, Cedars-Sinai Medical Center
17:30 Panel Discussion: Evolution of the Exosome Research Field
Johan Skog, Chief Scientific Officer, Exosome Diagnostics IncPanelists:Dominique de Kleijn, Professor, National University of Singapore
Xandra Breakefield, Professor, MGH
Shannon L. Stott, Professor, MGH
Pavan Kumar, Eisai
They have to be working on other biomarkers and tests. That is why we need a SHL.
CNN at 2.00 pm est today - A New Breakthrough for Alzheimer's. Would this be about AEMD ?
AEMD's new test for AD may be the " holy grail"
Biomarker World Congress
http://www.biomarkerworldcongress.com/Exosomes/
Dr. Taylor is presenting on day 2.
Diagnosing Alzheimer's disease (From UK)
http://www.nhs.uk/conditions/alzheimers-disease/pages/diagnosis.aspx
Biomarkers can predict risk for Alzheimer’s several years before symptoms appear
http://www.nia.nih.gov/newsroom/announcements/2013/06/biomarkers-can-predict-risk-alzheimers-several-years-symptoms-appear
http://www.nia.nih.gov/alzheimers/topics/diagnosis (Interesting video at the bottom - must see)
What new methods for diagnosing Alzheimer’s disease are being studied?
Scientists are exploring ways to help physicians diagnose Alzheimer’s disease earlier and more accurately. The ultimate goal is a reliable, valid, and inexpensive diagnostic test that can be used in any doctor’s office.
Some studies focus on changes in personality and mental functioning, measured through memory and recall tests, which might point to early Alzheimer’s or predict whether individuals are at higher risk of developing the disease. Other studies are examining the relationship between early damage to brain tissue and outward clinical signs.
Another very promising area of diagnostic research is the analysis of body fluids—blood and cerebrospinal fluid—to look for the proteins tau and beta-amyloid which are commonly found in people with Alzheimer’s. In addition, scientists have developed sophisticated imaging systems that may help measure the earliest changes in brain function or structure to identify people in the very first stages of Alzheimer’s—well before they develop obvious signs or symptoms.
So, what I am gathering from online information is a test for Alzheimer's would help in diagnosis and at the same time rule out other causes similar to Alzheimer's. The later is a good thing because in that case it would possibly be a treatable diagnosis for that person. We need AEMD to give us more info on this test …….
New 15-Minute At-Home Test May Detect Alzheimer's, Goes Viral
http://www.forbes.com/sites/melaniehaiken/2014/01/14/new-15-minute-at-home-test-may-detect-alzheimers-goes-viral/
http://www.medicalnewstoday.com/articles/271144.php
Treatments best started 'sooner than later'
Dr. Scharre notes that while the test does not diagnose Alzheimer's disease itself, it is a good tool that allows doctors to determine patients' initial cognitive function and to monitor this over time.
"We can give them the test periodically and, the moment we notice any changes in their cognitive abilities, we can intervene much more rapidly," he adds.
The Alzheimer's Association states that the number of people in the US with Alzheimer's disease aged 65 years and older is expected to almost triple to 13.8 million by the year 2050, and the researchers note that around 22% of people aged 60 years and over will have some form of mild cognitive impairment by this point.
But Dr. Scharre says he hopes that in enabling earlier detection of cognitive issues, the SAGE test will help in the treatment of these individuals.
"We are finding better treatments, and we know that patients do much better if they start the treatments sooner than later," he adds.
However, Dr. Doug Brown of the Alzheimer's Society in the UK notes that although the SAGE test is an "interesting development," home test are currently "not a reliable" way of diagnosing Alzheimer's disease or other types of dementia.
"Dementia and Mild Cognitive Impairment are difficult to diagnose, and we need to continue to fund more research into tests like this and other ways that may help improve the accuracy and ease of diagnosis," he adds.
Alzheimer's disease (From Mayo Clinic)
http://www.mayoclinic.org/diseases-conditions/alzheimers-disease/basics/tests-diagnosis/con-20023871
"There's no specific test today that confirms you have Alzheimer's disease. Your doctor will make a judgment about whether Alzheimer's is the most likely cause of your symptoms based on the information you provide and results of various tests that can help clarify the diagnosis."
"Lab tests
Blood tests may help your doctor rule out other potential causes of memory loss and confusion, such as thyroid disorders or vitamin deficiencies."
Tests for Alzheimer's Disease and Dementia
https://www.alz.org/alzheimers_disease_steps_to_diagnosis.asp
[b"]There is no single test that proves a person has Alzheimer's. A diagnosis is made through a complete assessment that considers all possible causes."
Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries
http://finance.yahoo.com/news/aethlon-medical-exosome-sciences-announce-132900731.html
CCBF Work Leads NIH to Invest in Exosome Research (from 3/2013)
http://www.childrenscbf.org/sites/default/files/Jounal%20of%20the%20NCI%203-2-13.pdf
NIH Awards Two Grants in February Supporting Research into microRNAs, Cancer
http://www.exosome-rna.com/nih-awards-two-grants-in-february-supporting-research-into-micrornas-cancer/?utm_source=Exosome+RNA+Subscribers&utm_campaign=7913bdb46c-RSS_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_15d51b9f02-7913bdb46c-77044969
Mortality among Persons in Care with Hepatitis C Virus Infection--The Chronic Hepatitis Cohort Study (CHeCS), 2006–2010
Reena Mahajan1, Jian Xing1, Stephen J. Liu1, Kathleen N. Ly1, Ann
http://cid.oxfordjournals.org/content/early/2014/02/11/cid.ciu077.abstract
Conclusions. HCV infection is greatly under-documented on death certificates. The 16,622 persons with HCV listed in 2010 may represent only one-fifth of about 80,000 HCV-infected persons dying that year, at least two-thirds of whom (53,000 patients) would have pre-mortem indications of chronic liver disease.
Shareholder letter!
Gilead's Hepatitis C Pill Takes Off Like A Rocket
http://www.forbes.com/sites/matthewherper/2014/02/21/gileads-hepatitis-c-pill-takes-off-like-a-rocket/?partner=yahootix
"It may be that other entrants, from AbbVie ABBV -1.58% or Merck, for instance, will prove good enough or inexpensive enough to take market share or even force a price war. It’s possible that insurance companies will push back." - This is were AEMD should figure in as an adjuvant.
2nd. Annual Circulating Biomarkers Conference
http://selectbiosciences.com/conferences/index.aspx?conf=CB2014
The potential of exosomes in diagnosis and treatment
http://www.exosome-rna.com/the-potential-of-exosomes-in-diagnosis-and-treatment-of-inborn-errors-of-metabolism/
Vball..
AEMD has one device the HP which is being modified to be used in different applications. This has been my understanding.
Sorry for the typos. Was trying to get all the posts in a short period of time in the morning.(Was always known for my knowledge of spelling or rather the lack of!)
We need a shareholder letter from JP giving us a better update on DARPA, exosome research, various patents involving exosomes, HCV study, our possible partners, etc.,
Milestone M5- I think this is the key for the proposed antisepsis machine. . To me it validates the HP as an antisepsis device. I say this because so far we knew it as an antiviral device (and of course an exosome capturer!). The company had not given much info on its ability to capture bacteria. There is no available drug or treatment for sepsis(except for possibly CTSO) This initiative by DARPA seems like a step before that - prevention of sepsis before it sets in by early detection and removal of the offending agents. From the 10qs, like the DARPA project is getting closer to completion. This machine if it works as planned may change the way sepsis is approached. If it was one company doing this, I would have been a sceptic. However, with the immense brainpower involved from the top institutions in the country and with milestones met regularly, I now feel that we shall see the antisepsis device.
From 10Q -
-Some of our patents may expire before we receive FDA approval to market our products in the United States or we receive approval to market our products in a foreign country. However, we believe that certain patent applications and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier(R) treatment technology.
-DARPA recently awarded a related contract to Battelle Memorial Institute (“Battelle”) to be the systems integrator for the various components being developed under the original contract, including our two components of the project. We agreed to become a subcontractor to Battelle under that systems integrator contract. That subcontract will be under a cost plus basis and we expect to begin generating revenues under the subcontract during the fiscal year ending March 31, 2014. Any revenues we derive under the subcontract will be at the direction of Battelle.
Better News for AEMD, from 10Q - Milestones met -
Milestone 2.3.2.2 – Formulate initial design work based on work from the previous phase. Begin to build and test selected instrument design and tubing sets. The milestone payment was $195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We demonstrated that we were able to formulate the initial design work and to build and test selected instrument design and tubing sets as part of our submission for approval. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.
Milestone 2.3.2.2 – Write and test software and conduct ergonomic research. Begin discussions with the systems integrator. The milestone payment was $195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We obtained wrote and tested software and conducted ergonomic research and began discussions with the systems integrator. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.
Milestone 2.3.3.2 – Cartridge construction with optimized affinity matrix design for each potential target. Complete the capture agent screening. The milestone payment was $208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We completed the cartridge construction with optimized affinity matrix design for each potential target and completed the capture agent screening. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.
Milestone M5 – Target capture > 90% in 24 hours for at least three targets in blood or blood components. The milestone payment was $208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We demonstrated that we were able to capture > 90% in 24 hours for at least three of the agreed targets in blood or blood components. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.
Good news, from 10Q :DARPA contract extension for years 3 to 5 (albeit less then expected). This was not not guaranteed before-
DARPA recently informed us that due to budget restrictions within the Department of Defense, that they planned to reduce the scope of our contract in years three through five of the contract. The reduction in scope will focus our research on exosomes, viruses and blood processing instrumentation. This scope reduction will reduce the possible payments under the contract by $858,491 over years three through five. While this contract change is not yet in place, we expect it to occur in the near future. We recently completed a rebudgeting of the expected costs on the remaining years of the DARPA contract based on the reduced milestones and have concluded that the reductions in our costs due to the scaled back level of work will almost entirely offset the anticipated revenue levels based on current assumptions. On February 10, 2014, DARPA finalized this contract modification.
Jeffpacman -
Thank you for all the upbeat messages on AEMD. I like your "cautious" optimism.
If one sees the research in the field of exosomes, it seems that there is tremendous potential. And it seems like now there is enough momentum, that it is going to continue. All the pieces slowly are falling together and while that is happening, looks like it is providing some answers, so far unknown, in the field of oncology.
My question, for a long time, has been what more applications does AEMD have for Oncology? We know a few vague things about exosomes. I have a very strong feeling that there is a lot going in the background at AEMD with respect to different fields of Cancer and what we know is only the tip of the iceberg.
Also, are there any thoughts for using the HP as a therapeutic agent? If the HP is successfully used in clinical trials for removing exosomes as a therapy (or as an adjuvant) even in one kind of cancer, then the sky will be the limit for AEMD. That will only open it up for other cancer therapies. The exosome field is already on a roll and I think we are lucky that it AEMD landed up as an exosome related company so early in the game. JJ needs a lot of credit for his foresight on this, associating with big players like M.D.Anderson and of course hiring Dr. Taylor.
However, over the next few years, the company may see more revenues from the DARPA sepsis program before revenues from exosomes. As we know there is no therapeutic agent for sepsis. DARPA took on this challenge and from the various PRs AEMD releases, it seems they are on track in the devise production. This will be revolutionary. If the final product does what DARPA wants it to be, this alone can open up the world market to AEMD and bring hug profits.
I am going to repeat something I have mentioned a few times before - esp. for Hep C, JJ should involve the Govt and insurance companies, show them that it is cost effective to use the HP and so consider it a standard of care along with other drugs. It may otherwise be hard to convince the medical field to embrace an invasive therapy (to be used with hemodialysis machines) to treat HepC, in spite of strong studies.
Thanks for the feedback. I tried hard for a while to make it work.
Identification of Immunoreactive Tumour Antigens Using Free and Exosome-Associated Humoral Responses (….Douglas Taylor is one of the authors). Sorry - link does not open the article!
http://www.intechopen.com/journals/exosomesandmicrovesicles/identification-of-immunoreactive-tumour-antigens-using-free-and-exosome-associated-humoral-responses
Cancer biomarkers: selecting the right drug for the right patient.
http://www.ncbi.nlm.nih.gov/pubmed/22322254?dopt=Abstract&holding=f1000,f1000m,isrctn
Opportunities and challenges of disease biomarkers: a new section in the journal of translational medicine
http://www.translational-medicine.com/content/10/1/220
Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study
http://www.translational-medicine.com/content/11/1/304/abstract
Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study
http://www.impactaging.com/papers/v5/n12/full/100624.html